Overview

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Irvine
Collaborator:
Pfizer
Treatments:
Angiogenesis Inhibitors
Axitinib